Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve. The deal centers on an exciting cardiovascular health ...

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.

Prime Medicine (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for Verve Therapeutics (NASDAQ:VERV) last month.

Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds. Click here to find out why ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, ...

Get the annual and quarterly balance sheet of Verve Therapeutics, Inc. (VERV) including details of assets, liabilities and shareholders' equity.

Verve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY. Per the terms, the pharma giant will acquire all outstanding shares of VERV for $10.50 per share in cash ...

Eli Lilly LLY-0.47%decrease; red down pointing triangle agreed to acquire Verve Therapeutics VERV 0.45%increase; green up pointing triangle for about $1 billion upfront, adding a potential ...

Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive agreement for Lilly ...

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...